What happened with OGI today?
No read yet
Uses news and trading volume to explain the day’s move and how it relates to the market.
Stop guessing. Get the call, a three-month target price, the best and worst cases, and a source for every claim.
Organigram Global Inc. supplies Canadian adult consumers with dried cannabis flower, pre-rolls, vapes and gummies under brands including SHRED and BOXHOT. Recreational sales account for most of its revenue. Provincial government bodies and large retailers buy its products and move them through their distribution networks to consumers; Organigram does not own or operate retail stores. A small number of customers account for a substantial share of sales, making their purchasing and product-listing decisions important to the business.
The company relies primarily on its Moncton Campus to grow cannabis, with other facilities processing and packaging products. Canadian production and sales require valid Health Canada licences, while the Cannabis Act restricts sales, branding and marketing.
A smaller revenue stream comes from supplying bulk cannabis to overseas cannabis companies for further processing and sale, including medical markets in Germany, Australia and the United Kingdom. Shipments require Canadian export and destination-country import approvals and permits. Organigram also sells hemp-derived THC beverages and edibles in the United States through local contract manufacturers, including Collective Project and happly products. It says a U.S. law scheduled to take effect in November 2026 would effectively eliminate these hemp-derived THC products unless amended or reversed, potentially requiring it to sell, wind down or restructure that business.
The risk section is the longest, dullest part of the filing. This keeps only what can really hurt you: where it hits, how hard, when it plays out.
Every company claims an edge. Each one is checked against hard numbers like margins and returns: which hold, and which line gives way first.
Cronos Group Inc. Common Share competes with Organigram for Canadian provincial wholesalers’ and retailers’ purchases of flower, pre-rolls and cannabis derivatives. Its Spinach and Lord Jones sales are worth watching for competition in these overlapping products.
Tilray Brands, Inc. and Organigram compete for Canadian adult-use and medical cannabis buyers, with both growing and selling cannabis. Tilray’s cannabis business is the relevant comparison, rather than its broader beverage and wellness businesses.
Canopy Growth Corporation competes with Organigram for Canadian adult-use cannabis buyers and medical cannabis customers abroad. Its medical business in Germany and Australia shows the direct overlap; its stated plan to supply the UK would extend that overlap.
Village Farms International, Inc. competes with Organigram through Pure Sunfarms and Rose LifeScience, which produce and sell branded cannabis to Canada’s recreational market. Those businesses, rather than Village Farms’ other operations, are the ones to watch for this competition.
British American Tobacco, which sells tobacco and nicotine products to adult consumers, funds Organigram’s international expansion as an equity investor and jointly develops cannabis technologies with it. Watch deployment of the CAD 59 million still available in the Jupiter Pool as of September 30, 2025, and commercialization of their jointly developed gummies, vapour and beverage innovations.
Aurora Cannabis Inc. competes with Organigram in Canadian and international medical cannabis, though Organigram relies much more on Canadian recreational sales. Aurora sells directly to registered Canadian patients; its expected reimbursement reduction of approximately 30% under the federal program change effective April 1, 2026 is a medical-market pressure to watch, not a measure of Organigram’s recreational business.
Sundial Growers Inc. (SNDL) competes with Organigram in growing and selling Canadian adult-use cannabis, while also selling cannabis to consumers through Value Buds and Spiritleaf stores. Watch its cannabis operations separately from liquor retail, which materially drives SNDL’s results.
High Tide Inc.’s Canadian cannabis stores and Organigram’s sales to wholesalers depend on spending by the same recreational consumers. High Tide’s Canadian store revenue is the useful demand signal: its Canadian bricks-and-mortar segment accounted for approximately 96% of total revenue in the fiscal year ended October 31, 2025.
Intercure Ltd. sources cannabis from Organigram through their strategic partnership for its medical cannabis distribution business, making it a customer rather than just a market comparison. Watch its demand for pharmaceutical-grade dried flower and oils distributed to pharmacies, which is relevant to its need for Organigram supply.
Cronos Group Inc. earningsCRON
Cronos Group's report will show whether its Spinach and Lord Jones products are holding sales in the Canadian categories where it competes with Organigram for wholesalers' and retailers' orders.
Read sales for Spinach and Lord Jones alongside Cronos's cannabis-business results. Steady or rising sales in those overlapping products show that Organigram still faces active competition; weaker sales may ease pressure from this rival, but do not show that Organigram has won the lost business.
Organigram Global Inc. earningsThis company
Organigram's report will show whether growth in recreational cannabis sales is bringing in more gross profit or whether price pressure and production costs are squeezing returns.
Read recreational net revenue, which excludes excise taxes, alongside gross margin as a percentage of net revenue. Rising sales with a stable or higher margin mean Organigram is earning more gross profit from its main sales channel; rising sales with a falling margin mean pricing or costs are eating into the gain; declines in both point to pressure on the core business.
